MCM
CMPX icon

MAI Capital Management’s Compass Therapeutics CMPX Stock Holding History

MAI Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1K Buy
14,189
+13,575
+2,211% +$40.1K ﹤0.01% 2024
2026
Q1 		$3.25K Buy
614
+590
+2,458% +$3.4K ﹤0.01% 3721
2025
Q4 		$129 Buy
+24
New +$111 ﹤0.01% 4123

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MAI Capital Management's CMPX Position: Q2 2026 in Review

MAI Capital Management increased its Compass Therapeutics (CMPX) stake by 2,211% in Q2 2026, buying an estimated $40.1K and bringing the position to 14,189 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

MAI Capital Management first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • MAI Capital Management held 14,189 shares of Compass Therapeutics worth $31.1K as of Q2 2026.
  • MAI Capital Management bought 13,575 Compass Therapeutics shares in Q2 2026, an estimated $40.1K.
  • Compass Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #2024 holding.
  • MAI Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.